Related Experiment Video
Updated: Jun 13, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Valganciclovir: recent progress
1Department of Surgery and Department of Microbiology/Immunology Indiana University, Indianapolis, IN, USA. mpescov@iupui.edu
Abstract:
In 2001 valganciclovir was approved by the FDA for treatment of HIV associated retinitis and in 2003 for prevention of post transplant CMV. This review provides an update on the status of its use and areas of controversy: How long should prophylaxis be given?; What is the appropriate dose for prophylaxis?; Can it be used in children, and at what dose?; Can it be used to treat CMV disease? The question of optimal dosing will probably not be settled as the sample size for controlled trials would be prohibitive. Other trials clearly show that extended therapy provides added benefit, the drug is safe and an appropriate dose has been identified in children and oral therapy of CMV disease is effective.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Cytomegalovirus Disease
Inhibitors Of Virion Release
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Genital Herpes
